Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Size: px
Start display at page:

Download "Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease"

Transcription

1 Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky, Hans-Ullrich Haase, Albert Schomig, Jürgen Pache, Adnan Kastrati Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der ISAR, Techniche Universität München, Munich, Germany

2 ABSTRACT Background: The impact of coronary atherosclerotic burden on prognosis and presentation of patients with coronary artery disease (CAD) is unknown. We investigated the association of coronary atherosclerotic burden with clinical outcome and presentation as unstable angina in patients with CAD. Methods: This study included patients with stable (n=8149) and unstable (n=2498) CAD who underwent percutaneous coronary intervention (PCI). Coronary atherosclerotic burden was assessed by Gensini score. The primary outcome analysis was 1-year mortality. Results: Gensini score was obtained by analysis of coronary segments. Patients were divided into groups according to quartiles of Gensini score: <13 (1st quartile; n=2650 patients), 13 to <25 (2nd quartile; n=2611 patients), 25 to <53 (3rd quartile; n=2711 patients) and >53 (4th quartile; n=2665 patients). There were 295 deaths during follow-up: 41 deaths in the 1st quartile, 42 deaths in the 2nd quartile, 83 deaths in the 3rd quartile and 129 deaths in the 4th quartile of Gensini score (Kaplan-Meier estimates of 1-year mortality 1.6%, 1.7%, 3.1% and 5.0%, respectively; adjusted hazards ratio [HR]=1.08, 95% confidence interval [CI] , P=0.007 for each 20-point increase in Gensini score). Gensini score was an independent correlate of presentation as unstable CAD (adjusted odds ratio [OR]=1.07, 95% CI , P, for each 20-point increase in the score). Coronary stenoses with 75% of lumen obstruction mediated almost all the increased risk related to the atherosclerotic burden for presentation as unstable CAD (adjusted OR=1.08, 95% CI , P). Conclusions: The present study showed that a higher coronary atherosclerotic burden is independently associated with increased risk of 1-year mortality in patients with stable and unstable CAD after PCI. The increased atherosclerotic burden is an independent correlate of presentation as unstable angina and the majority of risk for presentation as unstable angina is mediated by coronary stenoses with lumen narrowing of 75%.

3 BACKGROUND Transition from silent to clinically-overt coronary artery disease (CAD) is mostly related to the degree and speed of coronary obstruction leading to various degrees of myocardial ischemia. Rupture (or fissuring) of thin-cap atheromas with superimposition of thrombotic material is considered to be the underlying mechanism of acute coronary syndromes (ACS) in most, but not in all patients with CAD. Earlier serial angiographic studies showed that coronary occlusions resulting in ACS occur at the site of non-severe coronary artery stenoses in majority of patients. These studies supported the notion that mild to moderate coronary stenoses portend a higher risk for ACS than more severe stenoses which tend to remain unchanged. Recent studies in more contemporaneous series of patients disputed these views and showed that majority of acute myocardial infarctions occur at the site of significant stenoses and that intermediate coronary stenoses assessed by free-fractional reserve or intracoronary ultrasound show a very low event rate at long-term follow-up.

4 OBJECTIVES OF THE STUDY 1. To investigate the association of coronary atherosclerotic burden with mortality and other adverse events in a large series of consecutive patients with stable and unstable angina after percutaneous coronary intervention (PCI) 2. To compare angiographic coronary atherosclerotic burden in patients with stable and unstable angina and assessed the impact of coronary atherosclerotic burden on clinical presentation as unstable CAD

5 METHODS I Patients A consecutive series of patients with stable (n=8149) and unstable (n=2498) CAD undergoing coronary angiography and PCI between March 2000 and December Angiographic confirmation of significant disease (at least one coronary stenosis with 50% lumen obstruction). Patients with non-st-segment elevation myocardial infarction (chest pain plus elevated fourth-generation assay cardiac troponin T level >0.03 μg/l), ST-segment elevation myocardial infarction, renal disease (serum creatinine level 2 mg/dl), acute infections or known malignancies were excluded. The study has been carried out in accordance with the Declaration of Helsinki and has been approved by the institutional ethics committee.

6 METHODS II Angiographic evaluation Angiographic data were analyzed in the Angiographic Core Laboratory. CAD was confirmed by the presence of coronary stenoses 50% lumen obstruction in at least one of the three main coronary arteries. Coronary atherosclerotic burden was estimated by using Gensini score. Gensini GG: Am J Cardiol 1983; 51:606

7 METHODS III Outcome measurement The primary outcome: Secondary outcome: All-cause mortality at 1 year after PCI procedure Cardiovascular mortality Nonfatal myocardial infarction Stroke, Target lesion revascularization Major adverse cardiac events (a composite of death, nonfatal myocardial infarction and target lesion revascularization) Presentation as unstable CAD Follow-up A phone interview at 1 month, a visit at 6 months and a phone interview at 12 months after PCI procedure.

8 RESULTS I patients: 8149 patients with stable CAD n=2498 patients with unstable CAD Gensini score: Gensini score quartiles: coronary segments analyzed <13 (1st quartile; n=2650 patients) 13 to <25 (2nd quartile; n=2611 patients) 25 to <53 (3rd quartile; n=2711 patients) >53 (4th quartile; n=2665 patients)

9 Main Baseline Characteristics RESULTS II Characteristic Quartiles of Gensini score P value Age (years) 1st (n = 2650) 66.0 [58.3; 73.0] 2nd (n = 2611) 61.1 [59.5; 74.1] 3rd (n = 2721) 67.1 [60.1; 74.2] 4th (n = 2665) 69.0 [61.5; 75.4] Women 739 (27.9) 647 (24.8) 575 (21.1) 416 (15.6) Arterial hypertension 1899 (71.7) 1930 (73.9) 198 (73.1) 1984 (74.4) Hypercholesterolemia 1864 (70.3) 1865 (71.4) 2020 (74.2) 2128 (79.8) Diabetes 592 (22.3) 707 (27.1) 766 (28.2) 897 (33.7) Current smoker 420 (15.8) 347 (13.3) 319 (11.7) 293 (11.0) Prior myocardial infarction 733 (27.7) 738 (28.3) 921 (33.8) 1274 (47.8) Prior coronary artery bypass surgery 60 (2.3) 92 (3.5) 258 (9.5) 1317 (49.4) Presentation with unstable angina 518 (19.5) 582 (22.3) 699 (25.7) 699 (26.2) NYHA class Glomerular filtration rate /ml/min) 1669 (62.9) 826 (31.2) 142 (5.4) 13 (0.5) 82.9 [64.1; 105.2] 1562 (59.8) 874 (33.5) 162 (6.2) 13 (0.5) 81.1 [63.0; 101.2] 1472 (54.1) 1028 (37.8) 205 (7.5) 16 (0.6) 81.5 [61.8; 101.9] 1222 (45.8) 1154 (43.3) 263 (9.9) 26 (1.0) 77.3 [58.5; 100.1] C-reactive protein (mg/l) 2.00 [0.89; 5.28] 1.90 [0.84; 4.86] 2.00 [0.88; 5.18] 2.35 [0.98; 6.2] Number of affected coronary arteries (36.3) 431 (16.5) 259 (9.5) 71 (2.7) (34.9) 875 (33.5) 716 (26.3) 321 (12.0) (28.8) 1305 (50.0) 1746 (64.2) 2273 (85.3) Multivessel disease 1689 (63.7) 2180 (83.5) 2462 (90.5) 2594 (97.3)

10 RESULTS III Correlates of Presentation as Unstable CAD Independent Correlates of Presentation as Unstable CAD Variable Chisquare Adjusted odds ratio [95% confidence interval] P value C-reactive protein (for 5 mg/dl increase) [ ] Prior myocardial infarction [ ] Gensini score (for 20 points increase in severity) [ ] Female sex [ ] Current smoking [ ] Prior coronary artery bypass surgery [ ] Stenoses 75% were entered into the model this parameter (OR=1.08 [ ], P; chi-square =20.30) but not Gensini score (OR=1.02 [ ], P=0.210) predicted presentation as unstable CAD.

11 Clinical outcome RESULTS IV Characteristic Quartiles of Gensini score P value* 1st (n = 2650) 2nd (n = 2611) 3rd (n = 2721) 4th (n = 2665) All-cause mortality 41 (1.6) 42 (1.7) 83 (3.1) 129 (5.0) Cardiac mortality 24 (1.0) 24 (1.0) 60 (2.3) 81 (3.2) Nonfatal myocardial infarction 37(1.4) 67 (2.6) 95 (3.5) 120 (4.6) Stroke 6 (0.2) 13 (0.5) 16 (0.6) 16 (0.6) Target lesion revascularization 304 (11.8) 416 (16.4) 615 (23.7) 611 (24.3) Major adverse cardiac events 366 (14.1) 492 (19.2) 732 (27.6) 775 (30.0) Data are Kaplan-Meier estimates. * calculated with log-rank test.

12 Probability of mortality (%) P RESULTS V Kaplan-Meier Curves of All-Cause Mortality According to Gensini Score Quartiles 5.0% 3.1% 1.7% 1.6% Patients at risk Months 4th quartile rd quartile nd quartile st quartile

13 RESULTS VI Kaplan-Meier Estimates of 1-Year Mortality in Patients with Stable and Unstable CAD Probability of mortality (%) P Gensini score quartiles Stable CAD P Gensini score quartiles Unstable CAD

14 RESULTS VII Independent Correlates of 1-Year Mortality Variable Adjusted hazard ratio [95% confidence interval] P value Age (for 10-year increase in age) Gensini score (for 20 points increase in severity) Diabetes NYHA class (for 1 class increase in severity) 1.25 [ [ ] 1.56 [ ] 1.45 [ ] Prior coronary artery bypass surgery Glomerular filtration rate (for 10 ml/min decrease) 0.63 [ ] 1.20 [ ] C-reactive protein (for 5 mg/dl increase in concentration) 1.04 [ ] Left ventricular ejection fraction (for 10% decrease) 1.44 [ ]

15 CONCLUSIONS 1. A higher coronary atherosclerotic burden is independently associated with increased risk of 1-year mortality in patients with stable and unstable CAD after PCI. 2. The increased atherosclerotic burden is an independent correlate of presentation as unstable angina and the majority of risk for presentation as unstable angina is mediated by coronary stenoses with lumen narrowing of 75%.

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.

More information

Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes Journal of the American College of Cardiology Vol. 52, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.05.009

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators

More information

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 68, NO. 21, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 68, NO. 21, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 68, NO. 21, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER ISSN 0735-1097/$36.00 http://dx.doi.org/10.1016/j.jacc.2016.08.059

More information

Polymer-Free Stent CX - ISAR

Polymer-Free Stent CX - ISAR Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm

More information

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES. A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

PROMUS Element Experience In AMC

PROMUS Element Experience In AMC Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial

Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease FAME 2 Trial Clinicaltrials.gov NCT01132495 Bernard De Bruyne, Nico H.J. Pijls, William F Fearon, Peter Juni, Emanuele

More information

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches

More information

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Vascular Closure Devices Versus Manual Compression After Femoral Artery Access

Vascular Closure Devices Versus Manual Compression After Femoral Artery Access Vascular Closure Devices Versus Manual Compression After Femoral Artery Access the ISAR-CLOSURE Randomized Trial Stefanie Schüpke (Schulz) 1, Sandra Helde 1, Senta Gewalt 1, Tareq Ibrahim 2, Roland Schmidt

More information

The presenter does not have any potential conflicts of interest to disclose

The presenter does not have any potential conflicts of interest to disclose Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,

More information

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol

More information

Improved Noninvasive Assessment of Coronary Artery Bypass Grafts With 64-Slice Computed Tomographic Angiography in an Unselected Patient Population

Improved Noninvasive Assessment of Coronary Artery Bypass Grafts With 64-Slice Computed Tomographic Angiography in an Unselected Patient Population Journal of the American College of Cardiology Vol. 49, No. 9, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.066

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,

More information

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Statin pretreatment and presentation patterns in patients with acute coronary syndromes Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany

Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results

More information

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Prognostic value of multidetector computed tomography coronary angiography in a large population of patients with unknown cardiac disease but suspected

More information

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound

More information

The MAIN-COMPARE Registry

The MAIN-COMPARE Registry Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Exercise treadmill testing is frequently used in clinical practice to

Exercise treadmill testing is frequently used in clinical practice to Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD

More information

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang

More information

Clinical Trial Synopsis TL-OPI-516, NCT#

Clinical Trial Synopsis TL-OPI-516, NCT# Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus

More information

Intervention: How and to which extent is technology helping us?

Intervention: How and to which extent is technology helping us? Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction

More information

Predictive Factors for Early Cardiac Events and Angiographic Restenosis After Coronary Stent Placement in Small Coronary Arteries

Predictive Factors for Early Cardiac Events and Angiographic Restenosis After Coronary Stent Placement in Small Coronary Arteries Journal of the American College of Cardiology Vol. 40, No. 5, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02043-0

More information

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index SUPPLEMENTAL MATERIAL Supplemental Methods Duke CAD Index The Duke CAD index, originally developed by David F. Kong, is an angiographic score that hierarchically assigns prognostic weights (0-100) based

More information

Cindy L. Grines MD FACC FSCAI

Cindy L. Grines MD FACC FSCAI Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in

More information

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL

More information

Supplementary Table S1: Proportion of missing values presents in the original dataset

Supplementary Table S1: Proportion of missing values presents in the original dataset Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL

More information

Patient referral for elective coronary angiography: challenging the current strategy

Patient referral for elective coronary angiography: challenging the current strategy Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology

More information

Importance of the third arterial graft in multiple arterial grafting strategies

Importance of the third arterial graft in multiple arterial grafting strategies Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular

More information

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary

More information

FFR in Multivessel Disease

FFR in Multivessel Disease FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands

More information

Declaration of conflict of interest. Nothing to disclose

Declaration of conflict of interest. Nothing to disclose Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han

More information

Coronary Artery Disease: Revascularization (Teacher s Guide)

Coronary Artery Disease: Revascularization (Teacher s Guide) Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention

More information

How will new high sensitive troponins affect the criteria?

How will new high sensitive troponins affect the criteria? How will new high sensitive troponins affect the criteria? Hugo A Katus MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Even more sensitive: The new

More information

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial

Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial Journal of the American College of Cardiology Vol. 41, No. 8, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00119-0

More information

Fractional Flow Reserve and the Results of the FAME Study

Fractional Flow Reserve and the Results of the FAME Study Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine

More information

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,

More information

In-Ho Chae. Seoul National University College of Medicine

In-Ho Chae. Seoul National University College of Medicine The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering

More information

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Risk Factors of Cardiac Troponin T Elevation in Patients with Stable Coronary Artery Disease After Elective Coronary Drug-Eluting Stent Implantation Zhang-Wei Chen, MD; Ju-Ying

More information

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic

More information

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options?

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth

More information

FFR Incorporating & Expanding it s use in Clinical Practice

FFR Incorporating & Expanding it s use in Clinical Practice FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel

More information

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Adults With Diagnosed Diabetes

Adults With Diagnosed Diabetes Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et

More information

New Insight about FFR and IVUS MLA

New Insight about FFR and IVUS MLA New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,

More information

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular

More information

What do the guidelines say?

What do the guidelines say? Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

Thyroid Hormone and Coronary Artery Disease: From Clinical Correlations to Prognostic Implications

Thyroid Hormone and Coronary Artery Disease: From Clinical Correlations to Prognostic Implications Thyroid Hormone and Coronary Artery Disease: From Clinical Correlations to Prognostic Implications Address for correspondence: Michele Coceani, MD Via Moruzzi 1 56124 Pisa, Italy michecoc@ifc.cnr.it Michele

More information

Alex versus Xience Registry Preliminary report

Alex versus Xience Registry Preliminary report Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor

More information

Do stents deserve the bad press? Mark A. Tulli MD, FACC

Do stents deserve the bad press? Mark A. Tulli MD, FACC Do stents deserve the bad press? Mark A. Tulli MD, FACC Disclosures: None Introduction Stents don t help people. Stents are bad for patients. Heart Treatment Overused WSJ Study Finds Doctors Often Too

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

Use of Biomarkers for Detection of Acute Myocardial Infarction

Use of Biomarkers for Detection of Acute Myocardial Infarction Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine

More information

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized

More information

Uric acid and prognosis in angiography-proven coronary artery disease

Uric acid and prognosis in angiography-proven coronary artery disease DOI: 10.1111/eci.12039 ORIGINAL ARTICLE Uric acid and prognosis in angiography-proven coronary artery disease Gjin Ndrepepa *, Siegmund Braun *, Lamin King *, Massimiliano Fusaro *, Tomohisa Tada *, Salvatore

More information

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts

More information

Coronary Plaque Sealing: The DEFER Study and more...

Coronary Plaque Sealing: The DEFER Study and more... Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:

More information

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor

More information

Diabetes and Occult Coronary Artery Disease

Diabetes and Occult Coronary Artery Disease Diabetes and Occult Coronary Artery Disease Mun K. Hong, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory & Interventional Cardiology St. Luke s-roosevelt Hospital Center New York, New York

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

More information

Title for Paragraph Format Slide

Title for Paragraph Format Slide Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38

More information

Coronary interventions

Coronary interventions Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF

More information

Kavitha Yaddanapudi Stony brook University New York

Kavitha Yaddanapudi Stony brook University New York Kavitha Yaddanapudi Stony brook University New York 8 million ER visits a year for chest pain 2-10% have Acute coronary syndrome (ACS) Coronary CTA(CCTA) -safe alternative to standard of care (SOC) and

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen

More information

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, G. PAPANIKOLAOU GH, THESSALONIKI The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH

More information

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice

More information

Clinical Summary. Live Cases I - IX

Clinical Summary. Live Cases I - IX Clinical Summary Live Cases I - IX Case #1 2017/09/16 Age: 66 Target Vessel: RCA proximal Relevant Diagnosis: Single vessel CAD with normal LVEF Coronary Risk Factors: Hypertension, smoke (90py) ECG abnormality:

More information

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE Conflict of interest None to declare While IVUS is the most used intravascular

More information

Approach to Multi Vessel disease with STEMI

Approach to Multi Vessel disease with STEMI Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre

More information